Skip to main content

Posts

Showing posts with the label the next generation sequencing

Metagenomics Enhances Infectious Disease Surveillance

  Infectious lower respiratory diseases and diarrheal diseases are the leading causes of death globally . And the ongoing COVID-19 pandemic, which has contributed to 4.1 million deaths in 2019, once again is reminding the necessity of proactively identifying early signs of infectious disease outbreaks before things are getting worse. Conventional microbial diagnostics techniques would identify pathogens under specific culture conditions by serological detection of pathogen-associated antibodies or microbial genetic investigation using PCR, but these methods have been seen obvious shortcomings in pathogen coverage. It's highly required to find advanced scientific tools that are more sensitive even with a low microbial load or when targeted microorganisms are not suitable for  in vitro  culture, for which metagenomic approaches that can profile all DNA or RNA of a patient sample are increasingly catching the eyes of researchers.   How metagenomics can be used in infect...

The Next Generation Sequencing Advances Liquid Biopsy Companion Diagnostics for Precision Oncology

  The recognition and advancement of precision oncology are heavily attributed  to cancer genomics that can provide cancer molecular information, allowing researchers to tailor treatments and improve the outcome for a spectrum of cancer and other indications. To realize the promise of precision oncology, researchers take efforts to identify and discover relevant biomarkers using genomic profilin g , either for functional, diagnostic, predictive, or prognostic purposes.   The FDA's approval of two companion diagnostics  (CDx)—the Guardant360 CDx assay and the FoundationOne Liquid CDx test in 2020 led the testing of multi-gene mutations and biomarker profiling to a new level. Prior to the approval of these two companion diagnostics that involve a combination of liquid biopsy and next-generation sequencing (NGS) technology, researchers ha d been stuck with the low meaningful mutation frequency and the difficulty in finding biospecimens with specific mutations.   Tu...